Abstract
Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 177-184 |
| Number of pages | 8 |
| Journal | Journal of Neuroimmunology |
| Volume | 28 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1990 |
Fingerprint
Keywords
- Delayed-type hypersensitivity
- Experimental autoimmune encephalomyelitis
- Immunosuppression
- Myelin basic protein
- Recombinant β-galactoside binding human immunolectin
- T cell line
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Clinical Neurology
- Neurology
Cite this
Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. / Offner, Halina; Celnik, Bozena; Bringman, Timothy S.; Casentini-Borocz, Denise; Nedwin, Glenn E.; Vandenbark, Arthur.
In: Journal of Neuroimmunology, Vol. 28, No. 2, 1990, p. 177-184.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis
AU - Offner, Halina
AU - Celnik, Bozena
AU - Bringman, Timothy S.
AU - Casentini-Borocz, Denise
AU - Nedwin, Glenn E.
AU - Vandenbark, Arthur
PY - 1990
Y1 - 1990
N2 - Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.
AB - Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.
KW - Delayed-type hypersensitivity
KW - Experimental autoimmune encephalomyelitis
KW - Immunosuppression
KW - Myelin basic protein
KW - Recombinant β-galactoside binding human immunolectin
KW - T cell line
UR - http://www.scopus.com/inward/record.url?scp=0025309457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025309457&partnerID=8YFLogxK
U2 - 10.1016/0165-5728(90)90032-I
DO - 10.1016/0165-5728(90)90032-I
M3 - Article
C2 - 1694534
AN - SCOPUS:0025309457
VL - 28
SP - 177
EP - 184
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 2
ER -